Litigation Details for Teva Pharmaceuticals USA, Inc. v. Sandoz Inc. (D. Del. 2017)
✉ Email this page to a colleague
Teva Pharmaceuticals USA, Inc. v. Sandoz Inc. (D. Del. 2017)
| Docket | ⤷ Sign Up | Date Filed | 2017-05-24 |
| Court | District Court, D. Delaware | Date Terminated | 2019-03-29 |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | Defendant | Referred To | |
| Patents | 9,402,874 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Teva Pharmaceuticals USA, Inc. v. Sandoz Inc.
The small molecule drug covered by the patent cited in this case is ⤷ Sign Up .
Details for Teva Pharmaceuticals USA, Inc. v. Sandoz Inc. (D. Del. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2017-05-23 | 89 | a glatiramer acetate-related patent (United States Patent No. 9,402,874). Mylan and Sandoz filed counterclaims…prior to the expiration of U.S. Patent No. 9,155,775 (the “‘775 patent”). Pls.’ Compl. ¶ 1. The Product… 2016, the United States Patent and Trademark Office issued the ‘775 patent, entitled “Process for Manufacturing…owner of the patent, and has granted Teva USA an exclusive license under the ‘775 patent to use, offer… 3 patent under 35 U.S.C. § 271(b); contributory infringement of the ‘775 patent under 35 U.S.C | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
